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Purpose: Validating cases of acute liver injury (ALI) in health care data sources is
challenging. Previous validation studies reported low positive predictive values (PPVs).
Methods: Case validation was undertaken in a study conducted from 2009 to 2014
assessing the risk of ALI in antidepressants users in databases in Spain (EpiChron and
SIDIAP) and the Danish National Health Registers. Three ALI definitions were evalu-
ated: primary (specific hospital discharge codes), secondary (specific and nonspecific
hospital discharge codes), and tertiary (specific and nonspecific hospital and outpatient
codes). The validation included review of patient profiles (EpiChron and SIDIAP) and of
clinical data from medical records (EpiChron and Denmark). ALI cases were confirmed
when liver enzyme values met a definition by an international working group.
Results: Overall PPVs (95% CIs) for the study ALI definitions were, for the primary
ALI definition, 84% (60%‐97%) (EpiChron), 60% (26%‐88%) (SIDIAP), and 74% (60%‐
85%) (Denmark); for the secondary ALI definition, 65% (45%‐81%) (EpiChron), 40%
(19%‐64%) (SIDIAP), and 70% (64%‐77%) (Denmark); and for the tertiary ALI
definition, 25% (18%‐34%) (EpiChron), 8% (7%‐9%) (SIDIAP), and 47% (42%‐52%)
(Denmark). The overall PPVs were higher for specific than for nonspecific codes
and for hospital discharge than for outpatient codes. The nonspecific code “unspeci-
fied jaundice” had high PPVs in Denmark.
Conclusions: PPVs obtained apply to patients using antidepressants without
preexisting liver disease or ALI risk factors. To maximize validity, studies on ALI should
prioritize hospital specific discharge codes and should include hospital codes for unspec-
ified jaundice. Case validation is required when ALI outpatient cases are considered.
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KEY POINTS
• Case validation of acute liver injury (ALI) was conducted
in two Spanish databases, EpiChron and SIDIAP, and in
the Danish national registers.
• Validation of potential cases included patient profiles
review and adjudication based on clinical data extracted
from medical records.
• The overall PPVs obtained were higher for specific than
for nonspecific codes and for hospital discharge than for
outpatient codes.
• The nonspecific code “unspecified jaundice” had high
PPVs for all ALI definitions in Denmark but not in the
Spanish databases.
• To maximize validity, studies on ALI should prioritize
hospital specific discharge codes.
2 FORNS ET AL.1 | INTRODUCTION
Acute liver injury (ALI) is defined as a sudden appearance of liver test
abnormalities and includes a broad spectrum of clinical scenarios,
ranging from mild abnormal biochemical liver values to acute liver
failure.1,2
Previous validation studies have shown that identification of
potential ALI events through diagnosis and procedural codes is chal-
lenging and that most validated algorithms have positive predictive
values (PPVs) below 60%,3-5 except in one study, which reported
PPVs >75%.6 All previous studies highlight the need for validation by
medical record review when conducting studies of ALI based on auto-
mated health care data sources. This is especially important in drug
safety studies, in which reliance on algorithms alone for automated
case identification will most likely result in misclassification and over-
estimation of the true incidence of ALI and biased effect estimates.
As part of a recent post‐authorization safety study (PASS) con-
ducted in five European data sources investigating the potential risk
of ALI associated with the use of agomelatine and nine other antide-
pressant drugs,7 validation of the algorithms used to identify ALI cases
was conducted. This was done via medical record review in three of
those data sources: two Spanish health care databases and the Danish
National Health Registers.2 | METHODS
The objective of this study was to determine the ability of three ALI
definitions to correctly identify ALI cases in three automated health
care data sources. Specifically, we aimed to validate the following:
• An ALI definition including only main hospital discharge diagnosis
specific codes
• An ALI definition including main hospital discharge diagnosis
specific and nonspecific codes
• An ALI definition including main hospital discharge and also outpa-
tient diagnosis codes (both specific and nonspecific)2.1 | Study setting
Five automated health care databases were used in the agomelatine
PASS.7 Three of these were used to conduct a validation study: in
Spain, the EpiChron Cohort Study from Aragon Health Sciences Insti-
tute (Aragón, Spain)8 and the Information System for Research in Pri-
mary Care (SIDIAP) (Catalonia, Spain)9; and in Denmark, the Danish
National Health Registers (Denmark).10,11 The main characteristics of
each database are included in Supplementary eTable S1. Of the two
databases that were not used, validation by review of medical records
is not an option in the German Pharmacoepidemiological Research
Database (GePaRD) (Germany)12-14 and was not feasible within the
study timeframe in the Swedish National Registers (Sweden).15,16Nevertheless, an external validation study was conducted in
Germany,17 the results of which will be presented in a separate
publication.2.2 | Identification and definition of ALI
Cases of ALI were identified in cohorts of new users of the 10 study
antidepressants evaluated in the agomelatine PASS study between
2009 and 20147: citalopram, agomelatine, fluoxetine, paroxetine, ser-
traline, escitalopram, duloxetine, venlafaxine, mirtazapine, and amitrip-
tyline. Individuals aged 18 years or older at the date of their first‐
recorded prescription fill of any of the study antidepressants during
the study period(s) entered the cohort if they (a) had not received a
prescription fill for the same study antidepressant within the prior
12 months (new users) and (b) had at least 12 months of continuous
enrolment in the data source before the first prescription fill. Absence
of pregnancy at the start date of antidepressant use was an additional
inclusion criterion for women. Patients with a history of liver disease
or risk factors for liver disease (eg, alcohol and drug abuse and
dependence‐related disorders), chronic biliary or pancreatic disease,
malignancy, or other life‐threatening conditions (eg, HIV infection)
were excluded from the study cohort (Supplementary eMethods).
Three algorithms corresponding to three ALI definitions were used
in the agomelatine PASS to automatically identify potential ALI cases
based on diagnosis codes (Table 1).7,18 These definitions include com-
binations of codes that have shown higher (specific) or lower (nonspe-
cific) PPVs in previous validation studies.3-6 The primary ALI definition
was defined as any patient with a specific main hospital discharge
diagnosis code of ALI from either the International Classification of Dis-
eases, Ninth Revision, Clinical Modification (ICD‐9‐CM) or the Interna-
tional Statistical Classification of Diseases and Related Health Problems,
Tenth Revision (ICD‐100) (Table 2). The primary ALI definition was
TABLE 1 ICD‐9‐CM and ICD‐10 codes relevant to acute liver injury
Code Description
Specific codes
ICD‐9‐CM
570.x Acute and subacute necrosis of liver
572.2 Hepatic coma
573.3 Hepatitis unspecified
ICD‐10
K71.0 Toxic liver disease with cholestasis
K71.1 Toxic liver disease with hepatic necrosis
K71.2 Toxic liver disease with acute hepatitis
K71.6 Toxic liver disease with hepatitis, not elsewhere
classified
K71.9 Toxic liver disease, unspecified
K72.0 Acute and subacute hepatic failure
K72.9 Hepatic failure, unspecified
K75.9 Inflammatory liver disease, unspecified
K76.2 Central hemorrhagic necrosis of liver
Nonspecific codes
ICD‐9‐CM
573.8 Other specified disorders of liver
573.9 Unspecified disorders of liver
782.4 Jaundice, unspecified, not of newborn
V42.7 Liver transplant
790.4 Nonspecific elevation of transaminase or lactic acid
dehydrogenase
789.1 Hepatomegaly
ICD‐10
K76.8 Other specified diseases of liver
K76.9 Liver disease, unspecified
R17 Unspecified jaundice, excludes neonatal
R16.0 Hepatomegaly, not elsewhere classified
R16.2 Hepatomegaly with splenomegaly, not elsewhere
classified
R74.0 Nonspecific elevation of transaminase and lactic acid
dehydrogenase
Z94.4 Liver transplant
ICPC
D97 Liver disease (specified or unspecified)
D13 Jaundice
D23 Hepatomegaly
A91 Abnormal results investigations
Abbreviations: ICD‐9‐CM, International Classification of Diseases, Ninth
Revision, Clinical Modification; ICD‐10, International Statistical Classification
of Diseases and Related Health Problems, Tenth Revision; ICPC, International
Classification of Primary Care.
FORNS ET AL. 3not validated per se, but the specific codes identifying the primary ALI
definition were included in the secondary ALI definition, which
underwent validation. The algorithm used to identify potential casesof the secondary study ALI definition was defined as any patient with
a main hospital specific or nonspecific discharge code (ICD‐9‐CM or
ICD‐10) for ALI. Finally, the algorithm for the tertiary ALI definition
was assessed using specific and nonspecific codes from either ICD‐
9‐CM or ICD‐10 identified in both hospital and outpatient settings.
In EpiChron, International Classification of Primary Care (ICPC) codes
were used to identify outpatient cases of the tertiary ALI definition
and ICD‐9‐CM to identify hospital cases. In SIDIAP, ICD‐10‐CM was
used to identify primary care diagnoses and ICD‐9‐CM to identify hos-
pital cases. In Denmark, primary care codes were not available, and
therefore only hospital ICD‐10 codes were used both for case identi-
fication and to apply exclusion criteria. The interplay between the
three ALI definitions is displayed in Figure 1.2.3 | Diagnostic criteria for ALI
Potential cases of ALI identified with the electronic algorithms and
reviewed by adjudicators were considered confirmed (true positives)19
if any of the following three qualifying criteria for increases in serum
levels with <1 year of persistence were met (aspartate transaminase
[AST] levels could be used instead of ALT levels only if ALT levels
were unavailable and there was no known muscle pathology driving
the rise in AST):
• ≥ 5 x upper limit of normal (ULN) alanine aminotransferase (ALT)
• ≥ 2 x ULN alkaline phosphatase (ALP)
• ≥ 3 x ULN ALT and > 2 x ULN bilirubin
The requirement of less than 1 year of persistence of the liver func-
tion test abnormalities was introduced to ensure that cases had ALI
and not chronic liver injury.19 This criterion was evaluated using the
most recent liver enzymes results from the period 12 to 24 months
before the index date to check whether they were not elevated
beyond 10% of the ULN (if no results were available, the criterion
was considered as met).
A false‐positive case of ALI was defined as a potential case with
enough data to be evaluated but that did not meet the criteria to be
classified as a confirmed case of ALI. A nonevaluable case of ALI was
defined as a potential case that lacked some of the required liver
enzyme results to be evaluated.2.4 | Validation steps
The strategy for validating potential cases identified by automated
algorithms across the three data sources included up to three steps:
review of patient profiles (which is a deidentified chronological listing
of medical events and drug prescriptions and is used to detect exclu-
sion diagnoses missed by the electronic algorithm and to provide an
initial assignment of case status), medical record abstraction of rele-
vant clinical data by trained health care professionals, and review of
abstracted data and case adjudication by trained physicians. However,
local adaptations were required in Denmark and SIDIAP to reflect data
TABLE 2 Positive predictive values (PPVs) of study ALI definitions and of overall specific and nonspecific codes used to identify potential acute
liver injury (ALI) cases (nonevaluable cases not included)
EpiChron SIDIAP Denmark
Totala TP PPV, % (95% CI)b Totala TP PPV, % (95% CI)b Totala TP PPV, % (95% CI)b
Secondary ALI definition 31 20 64.5 (45.4‐80.8) 20 8 40.0 (19.1‐63.9) 213 150 70.4 (63.8‐76.5)
Specific codesc 19 16 84.2 (60.4‐96.6) 10 6 60.0 (26.2‐87.8) 50 37 74.0 (59.7‐85.4)
Nonspecific codes 12 4 33.3 (9.9‐65.1) 10 2 20.0 (2.5‐55.6) 163 113 69.3 (61.6‐76.3)
Tertiary ALI definition 134 34 25.4 (18.3‐33.6) 2,242 172 7.7 (6.6‐8.9) 443 208 47.0 (42.2‐51.7)
Specific codes 18 15 83.3 (58.6‐96.4) 46 16 34.8 (21.4‐50.2) 73 50 68.5 (56.6‐78.9)
Nonspecific codes 116 19 16.4 (10.2‐24.4) 2,196 156 7.1 (6.1‐8.3) 370 158 42.7 (37.6‐47.9)
Abbreviations: CI, confidence interval; SIDIAP, Information System for Research in Primary Care; TP, true positives.
aTotal of evaluable cases. Nonevaluable cases for the secondary and tertiary ALI definitions were 9 and 104 in EpiChron, 14 and 584 in SIDIAP, and 28 and
66 in Denmark.
bPPV was calculated as PPV = confirmed cases / (true positives + false positives). Results are presented as positive predictive values (%) and their 95% CIs.
cEquivalent to the PPVs for the study primary ALI definition (specific hospital discharge codes).
FIGURE 1 Definition of the study ALI definition algorithmsa
aALI definition refers to the case‐identifying algorithms only. By
definition, the secondary ALI definition in the analysis included only
cases confirmed after validation. [Colour figure can be viewed at
wileyonlinelibrary.com]
4 FORNS ET AL.availability and/or local regulations (Supplementary eTable S2). In
Denmark, patient profiles were not reviewed due to the very limited
clinical information available. Also, primary care data were not
available. Finally, patients with study exclusion criteria not identified
by hospital codes were excluded during either the abstraction or the
review of the abstracted information from medical records. In SIDIAP,
source hospital medical records were not accessible; therefore, patient
profile review relied only on liver enzyme results available from pri-
mary care and yielded the final case classifications in this database.
Cases were reviewed both by trained physicians for all secondary
ALI definition potential cases and by an electronic algorithm for
the tertiary ALI definition due to the large number of identified
potential cases.
Several quality control checks and measures were performed. All
the health care professionals at each site involved in the validation,including nurses, clinical pharmacists and physicians, received training
on the validation processes. In EpiChron, for quality control purposes,
patient profiles of a random sample of 10 potential cases were
reviewed independently by a second physician and a random sample
of 25% of the confirmed cases and of 10 inpatient nonevaluable cases
also were reviewed by a second physician. In SIDIAP, for the tertiary
ALI definition, an electronic algorithm evaluated all potential cases,
and 10% of them were also evaluated manually by trained profes-
sionals blinded to the study exposure. A very high level of agreement
(kappa statistic equal to or larger than 0.95) between the algorithm
and the manual reviewers was obtained before the algorithm was gen-
eralized; agreement between the two clinician reviewers was also
assessed (kappa statistic = 1). Similarly, in Denmark, an algorithm
was created to evaluate potential cases. Trained physicians manually
reviewed 50 potential cases, all of which were also reviewed using
the automated algorithm. All potential cases were evaluated using
the automated algorithm only after the kappa measuring the agree-
ment between manual review and the algorithm reached 1.2.5 | Statistical analyses
Validity of the electronic algorithms and individual codes used to iden-
tify potential cases of ALI for the secondary and tertiary ALI defini-
tions were assessed by calculating the overall PPV of the algorithm,
the overall PPVs of the specific and nonspecific codes, and the PPV
of each individual code. PPVs for the primary ALI definition were
indirectly calculated through the specific codes of the secondary ALI
definition. The PPV was calculated as true positives / (true posi-
tives + false positives). In a sensitivity analysis, nonevaluable cases
were included in the PPV denominator.
The PPVs were computed with 95% confidence intervals (CIs) for
binomial proportions by the exact method using Stata software20—
version 12 at EpiChron and version 14 at Denmark. At SIDIAP, SAS
statistical software (version 9.4; SAS Institute, Inc; Cary, North
Carolina) and R software version 3.3.1 were used.
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The number of users of antidepressants and the final number of new
users (after applying inclusion/exclusion criteria) in the three data-
bases in which validation of potential cases was conducted are
included Supplementary eTable S3. In EpiChron, SIDIAP, and
Denmark, 59, 34, and 489 potential cases of the secondary ALI defini-
tion, respectively, were identified; and 268, 2826, and 1008 potential
cases of the tertiary ALI definition were identified. Then, 31, 20, and
213 potential cases of the secondary ALI definition were considered
evaluable cases; and 134, 2242, and 443 potential cases of the tertiary
ALI definition were considered evaluable cases. Of them, 20, 8, and
150 cases of the secondary ALI definition and 34, 172, and 208 cases
of the tertiary ALI definition were confirmed (true positives) after
validation (Figure 2).FIGURE 2 Flowchart with the flow of
potential cases through the case validation
process: Secondary (regular font) and tertiary
(italics) ALI definitions [Colour figure can be
viewed at wileyonlinelibrary.com]
Note: In each cell, the first number refers to secondary ALI definitions, an
fifteen patients did not undergo further validation due to the lack of addit
excluded based on the presence of exclusion or censoring criteria and did n
on ambulatory codes and with lack of additional hospital data were directly
classified as true positives, 69 as false positives, and 35 were considered n
hospital codes were excluded during the abstraction or review of medicalRegarding the tertiary ALI definition, which includes the total num-
ber of cases for all ALI definitions (see Figure 1), more than 70% of
true positives in Denmark and SIDIAP and 56% of true positives in
EpiChron were females. Overall, the age group with the highest num-
ber of true positives was patients 80 years and older, followed by
patients aged 50 to 79 years (Supplementary eTable S4).
The overall PPVs for the algorithm used to identify potential cases
of the secondary ALI definition were 65% (95% CI, 45%‐81%) in
EpiChron, 40% (95% CI, 19%‐64%) in SIDIAP, and 70% (95% CI,
64%‐77%) in Denmark (Table 2). As discussed in the Methods section,
the primary ALI definition was indirectly validated through the specific
hospital discharge codes used in the secondary ALI definition, for which
the overall PPVs were 84% (95% CI, 60%‐97%) in EpiChron, 60% (95%
CI, 26%‐88%) in SIDIAP, and 74% (95% CI, 60%‐85%) in Denmark. The
overall PPVs for the specific codes were higher than those for thed the second number refers to tertiary ALI definitions.a One hundred
ional hospital data for those cases. Among them, eight patients were
ot undergo further validation.b One hundred seven patients identified
adjudicated during the patient profile phase. Among them, three were
onevaluable.c Patients with study exclusion criteria not identified by
records.
6 FORNS ET AL.nonspecific codes in all data sources (Table 2). In EpiChron and SIDIAP,
the individual specific code 570.x (acute and subacute necrosis of liver)
had the highest PPV, while the code 573.3 (hepatitis unspecified) cap-
tured the highest proportion of true positives (Table 3). In Denmark,
the individual specific codes K71.2 (toxic liver disease with acute hepa-
titis) and K71.6 (toxic liver disease with hepatitis, not elsewhere speci-
fied) obtained the highest PPVs and captured the highest proportion of
true positives (Table 4). None of the nonspecific codes captured more
than two true positives in EpiChron and SIDIAP (Table 3). Conversely,
in Denmark, the individual nonspecific code R17 (unspecified jaundice,
excludes neonatal) contributed the largest number of true positives andTABLE 3 Positive predictive values (PPVs) of specific and nonspecific co
(regular font) and tertiary (italics) ALI definitions in data sources using ICD
EpiChron
Total TP PPV, % (95%
Specific codes
570.x Acute and subacute necrosis of liver
Secondary ALI definition 5 5 100.0 (4
Tertiary ALI definition 5 5 100.0 (4
572.2 Hepatic coma
Secondary ALI definition 1 0 0.0 (0
Tertiary ALI definition 1 0 0 (0‐97.5)
573.3 Hepatitis unspecified
Secondary ALI definition 13 11 84.6 (5
Tertiary ALI definition 12 10 83.3 (5
Nonspecific codes
573.8 Other specified disorders of liver
Secondary ALI definition 9 2 22.2 (2
Tertiary ALI definition 9 2 22.2 (2
573.9 Unspecified disorders of liver
Secondary ALI definition 1 0 0.0 (0
Tertiary ALI definition 0 0 ‐
782.4 Jaundice, unspecified, not of newborn
Secondary ALI definition 1 1 100 (2.5‐10
Tertiary ALI definition 1 1 100 (2.5‐10
V42.7 Liver transplant
Secondary ALI definition 0 ‐ ‐
Tertiary ALI definition 0 ‐ ‐
790.4 Nonspecific elevation of transaminase or LDH
Secondary ALI definition 1 1 100.0 (2
Tertiary ALI definition 1 1 100.0 (2
789.1 Hepatomegaly
Secondary ALI definition 0 ‐ ‐
Tertiary ALI definition 0 ‐ ‐
Abbreviations: CI, confidence interval; ICD‐9‐CM, International Classification of
nase; TP, true positives.
Note: PPVs for the ICPC codes used to define cases for the tertiary ALI definit
aPPV was calculated as PPV = confirmed cases / (true positives + false positiveshad the highest PPV among all individual specific or nonspecific hospi-
tal discharge codes.
For the tertiary ALI definition, the overall PPVs were 25% (95% CI,
18%‐34%) in EpiChron, 8% (95% CI, 7%‐9%) in SIDIAP, and 47% (95%
CI, 42%‐52%) in Denmark. As observed for the secondary ALI defini-
tion, we observed higher PPVs for specific than nonspecific codes in
all data sources (Table 2). Among the individual specific codes, 570.x
(acute and subacute necrosis of liver) had the highest PPV in EpiChron
and SIDIAP (Table 3 and Supplementary eTable S5). In Denmark, code
K71.2 (toxic liver disease with acute hepatitis) had the highest PPV
among specific codes (Table 4). Among the nonspecific codes, 782.4des used to identify potential acute liver injury (ALI) cases: Secondary
‐9‐CM codes (nonevaluable cases not included)
SIDIAP
CI)a Total TP PPV, % (95% CI)a
7.82‐100.0) 3 3 100.0 (29.2‐100.0)
7.8‐100.0) 1 1 100.0 (2.5‐100.0)
.0‐97.5) 0 ‐ ‐
0 ‐ ‐
4.6‐98.1) 7 3 42.9 (9.9‐81.6)
1.6‐97.9) 4 3 75.0 (19.4‐99.4)
.8‐60.0) 6 0 0.0 (0.0‐45.9)
.8‐60.0) 5 0 0.0 (0.0‐52.2)
.0‐97.5) 0 0 ‐
0 0 ‐
0) 2 2 100 (15.8‐100)
0) 2 2 100 (15.8‐100)
0 ‐ ‐
0 ‐ ‐
.5‐100.0) 2 0 0.0 (0.0‐84.2)
.5‐100.0) 1 0 0.0 (0.0‐97.5)
0 0 ‐
0 0 ‐
Diseases, Ninth Revision, Clinical Modification; LDH, lactic acid dehydroge-
ion in EpiChron are presented in eTable 5.
). Results are presented as positive predictive values (%) and their 95% CIs.
TABLE 4 Positive predictive values (PPVs) of specific and nonspecific codes used to identify potential acute liver injury (ALI) cases: Secondary
(regular font) and tertiary (italics) ALI definitions in data sources using ICD‐10‐CM codes (nonevaluable cases not included)
SIDIAPa Denmarkb
Total TP PPV, % (95% CI)c Total TP PPV, % (95% CI)c
Specific codes
K71.0 Toxic liver disease with cholestasis
Secondary ALI definition n < 5 n < 5 50.0 (1.3–98.7)
Tertiary ALI definition 0 ‐ ‐ 5 n < 5 60.0 (14.7‐94.7)
K71.1 Toxic liver disease with hepatic necrosis
Secondary ALI definition 5 n < 5 40.0 (5.3‐85.3)
Tertiary ALI definition 0 ‐ ‐ 6 n < 5 33.3 (4.3‐77.7)
K71.2 Toxic liver disease with acute hepatitis
Secondary ALI definition 9 8 88.9 (51.8‐99.7)
Tertiary ALI definition 0 ‐ ‐ 13 12 92.3 (64.0‐99.8)
K71.6 Toxic liver disease with hepatitis, not elsewhere classified
Secondary ALI definition 8 7 87.5 (47.3‐99.7)
Tertiary ALI definition 5 2 40.0 (5.3‐85.3) 9 8 88.9 (51.8‐99.7)
K71.9 Toxic liver disease, unspecified
Secondary ALI definition 5 n < 5 80.0 (28.4‐99.5)
Tertiary ALI definition 1 0 0.0 (0.0‐97.5) 12 6 50.0 (21.1‐78.9)
K72.0 Acute and subacute hepatic failure
Secondary ALI definition 7 6 85.7 (42.1‐99.6)
Tertiary ALI definition 3 2 66.7 (9.4‐99.2) 9 8 88.9 (51.8‐99.7)
K72.9 Hepatic failure, unspecified
Secondary ALI definition 10 6 60.0 (26.2‐87.8)
Tertiary ALI definition 8 1 12.5 (0.3‐52.7) 13 7 53.8 (25.1‐80.8)
K75.9 Inflammatory liver disease, unspecified
Secondary ALI definition n < 5 n < 5 66.7 (9.4‐99.2)
Tertiary ALI definition 23 7 30.4 (13.2‐52.9) 5 n < 5 60.0 (14.7‐94.7)
K76.2 Central hemorrhagic necrosis of liver
Secondary ALI definition n < 5 n < 5 100 (2.5‐100)
Tertiary ALI definition 0 ‐ ‐ n < 5 n < 5 100 (2.5‐100)
Nonspecific codes
K76.8 Other specified diseases of liver
Secondary ALI definition 16 n < 5 6.3 (0.2‐30.2)
Tertiary ALI definition 111 1 0.9 (0.0‐4.9) 35 n < 5 11.4 (3.2‐26.7)
K76.9 Liver disease, unspecified
Secondary ALI definition 30 15 50.0 (31.3‐68.7)
Tertiary ALI definition 116 11 9.5 (4.8‐16.3) 107 33 30.8 (22.3‐40.5)
R17 Unspecified jaundice, excludes neonatal
Secondary ALI definition 79 75 94.9 (87.5‐98.6)
Tertiary ALI definition 57 20 35.1 (22.9‐48.9) 90 82 91.1 (83.2‐96.1)
R16.0 Hepatomegaly, not elsewhere classified
Secondary ALI definition 7 n < 5 42.9 (9.9‐81.6)
Tertiary ALI definition 52 3 5.8 (1.2‐15.9) 12 n < 5 25.0 (5.5‐57.2)
(Continues)
FORNS ET AL. 7
TABLE 4 (Continued)
SIDIAPa Denmarkb
Total TP PPV, % (95% CI)c Total TP PPV, % (95% CI)c
R16.2 Hepatomegaly with splenomegaly, not elsewhere classified
Secondary ALI definition n < 5 n < 5 75.0 (19.4‐99.4)
Tertiary ALI definition 0 ‐ ‐ 6 n < 5 50.0 (11.8‐88.2)
R74.0 Nonspecific elevation of transaminase and LDH
Secondary ALI definition 27 16 59.3 (38.8‐77.6)
Tertiary ALI definition 1,852 119 6.4 (5.4‐7.6) 120 33 27.5 (19.7‐36.4)
Z94.4 Liver transplant
Secondary ALI definition 0 ‐ ‐
Tertiary ALI definition 0 ‐ ‐ 0 ‐ ‐
Abbreviations: CI, confidence interval; ICD‐10‐CM, International Classification of Diseases, Tenth Revision, Clinical Modification; LDH, lactic acid dehydroge-
nase; TP, true positives.
aIn SIDIAP, ICD‐10 codes were used only for the outpatient codes of the study tertiary ALI definition.
bDue to data protection policies in Denmark, the exact number of cases could not be provided when the number of cases was less than five.
cPPV was calculated as PPV = confirmed cases / (true positives + false positives). Results are presented as positive predictive values (%) and their 95% CIs.
8 FORNS ET AL.(jaundice, unspecified, not of newborn) had the highest PPV in both
EpiChron and SIDIAP, although it had a low number of confirmed
cases (one and two true positives in EpiChron and SIDIAP, respec-
tively). In Denmark, ICD‐10 code R17 (unspecified jaundice, excludes
neonatal) had the highest PPV (91%) and contributed the largest
number of true positives. In SIDIAP, the same code used to identify
primary care diagnoses had the second highest PPV, and it was also
the second highest contributor of true positives. Regarding code
R74.0 (nonspecific elevation of transaminase or LDH), in SIDIAP, it
was the code with the highest number of true positives, although it
had a low PPV (6%).
In the sensitivity analysis including nonevaluable cases in the
denominator of the PPV calculation, the overall PPVs for all study
ALI definitions and for both specific and nonspecific codes were
smaller than those for the main PPV analysis in all data sources (see
Supplementary eTables S6 and S7).4 | DISCUSSION
We observed consistently higher overall PPVs for specific ALI codes
versus nonspecific codes and higher overall PPVs for hospital dis-
charge codes versus outpatient codes. The identification of ALI cases
based on hospital discharge specific codes, considered as the primary
ALI definition in this study, resulted in higher PPVs when compared
with most previously described algorithms.3-6
In contrast to the present study, previous studies conducted to val-
idate ALI cases have reported PPVs below 60%,3-5 or around 75%.6 A
recently published systematic review and meta‐analysis including 29
studies validating ALI or drug‐induced liver injury (DILI) (25 of them
presenting PPVs) showed a pooled PPV estimate for ALI of 13.4%
(95% CI, 6.1%‐22.8%) and for DILI of 15.3% (95% CI, 9.5%‐22.2%).21
The authors of that study suggested that the low PPVs observed inthe studies might be explained by the low prevalence of ALI or DILI.
In addition, a different list of diagnosis codes, laboratory threshold
criteria, and study drugs might be the cause of the differences
between studies. When we compared our study with previous studies
validating ALI definitions, we observed that our study differed from
these previous studies in different ways: Bui et al6 did not exclude
patients with hepatic, biliary, or pancreatic diseases or cancer; Lo Re
et al3 included only cases of severe ALI; Udo et al5 validated cases
of idiopathic ALI only; and Traversa et al4 validated cases of ALI asso-
ciated with the use of nonsteroidal antiinflammatory drugs. In addi-
tion, there are differences in the type of data sources: the Bui et al6
and Lo Re et al3 studies were conducted in claims databases including
inpatient and outpatient encounters, prescriptions, and laboratory
tests. The Traversa et al4 and Udo et al5 studies were conducted in
hospital databases in a way similar to the Danish component of our
study. There are also differences in the ALI definition used in previous
studies compared with the criteria used in our study, which were
based on Aithal criteria.19
Positive predictive values obtained in the present study for the
ICD‐9 specific codes 573.3 (hepatitis unspecified) and 570.x (acute
and subacute necrosis of liver) and specific ICD‐10 codes K71.2
(toxic liver disease with acute hepatitis) and K71.6 (toxic liver disease
with hepatitis, not elsewhere specified) were in line with previous
studies. In Udo et al,5 the code 573.3 had a PPV of 80%. In Bui
et al,6 the PPV for individual code 570.x was 84% and for 573.3
was 76%, while the PPV for the algorithm including codes 570.x,
572.2 (hepatic coma), or 573.3 was 74%. In Lo Re et al,3 the PPVs
for individual codes ranged from 6.5% to 54.3%, the combination
of codes 570.x with 572.8 (sequelae of liver disease; hepatic failure)
had a PPV of 100%, and code 570.x in combination with 572.2 had a
PPV of 67%. In addition, the authors calculated PPVs including
patients with preexisting liver disease, and the PPVs were higher
when compared with the subset of the population that excluded
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(DILI),22,23 code 573.3 (hepatitis unspecified) was the highest con-
tributor of DILI cases.
In the present study, the nonspecific code for unspecified jaundice
(R17) obtained high PPVs, and it was the highest contributor of true
positives in Denmark. In EpiChron and SIDIAP databases, the ICD‐9‐
CM code 782.4 (jaundice, unspecified, not of newborn) had high PPVs
for the secondary ALI definition (hospitalized cases), although the
number of true positives was one and two cases, respectively. In
SIDIAP, the ICD‐10 code for unspecified jaundice used in the tertiary
ALI definition to validate hospitalized and outpatient cases was the
second contributor of true positives and had the second‐highest
PPV, although it was low (35%). Potential explanations for this
discrepancy in the results for unspecified jaundice code between
Denmark and Spanish data sources could be the following: (a) in
Denmark, only hospitalized and outpatient cases from hospital outpa-
tient clinics are validated; and (b) in Denmark, exclusion criteria not
identified previously were applied, if identified, during either the
abstraction or the review of the abstracted information from medical
records. These reasons may reduce the presence of false positives
and justify the high PPV observed for this code in Denmark compared
with Spanish data sources. Results observed in Denmark also contrast
with those in a previous study,23 which reported that the nonspecified
code for unspecified jaundice identified only a small proportion of DILI
cases (5% of the 265 cases in Shin et al23 vs 39% of the 208 cases of
the tertiary ALI definition confirmed in Denmark observed in our
study), but the differences when validating ALI or DILI cases must be
taken into account. In addition, the study by Shin et al23 was not
restricted to hospital cases as it was in Denmark, and thus the preva-
lence of true ALI in populations including outpatient primary care
cases should be lower, which would explain the differences observed
between the two studies.4.1 | Strengths and limitations
In terms of number of validated cases, the present validation study
represents one of the largest efforts performed in Europe to validate
ALI cases identified in automated health care databases, using case‐
identifying algorithms, and confirmed according to consensus criteria
based on the presence of elevated liver enzyme levels in blood. In
addition, to the best of our knowledge, this study is the first to vali-
date ICD‐10 codes related to ALI. However, the results obtained in
the present study must be evaluated in the context of its limitations.
An important limitation of this study is that, although the ALI defini-
tions were consistent across data sources and based on blood liver
enzyme levels, the approach to the evaluation of potential cases
was adapted to the type of information and local resources available
for the validation efforts, which may have impacted our findings. In
SIDIAP, the validation was partial for all potential cases (inpatient
and outpatient), based only on liver enzyme results from primary
care, and no hospital medical records to validate hospital cases were
available. That could explain the lowest PPV for the secondary ALIdefinition in SIDIAP. In Denmark, only outpatient potential cases
from hospital outpatient clinics could be identified (primary care data
were not available). This is probably the reason why the difference in
PPVs between specific and nonspecific codes was smaller in
Denmark than in the other data sources, and it would also explain
the higher PPVs obtained in Denmark for the secondary and tertiary
ALI definitions compared with the two Spanish data sources. For
some codes, the number of cases was low, resulting in wide CIs for
the PPV. The present study has also other limitations. First, we did
not conduct validation of false positives, and therefore negative pre-
dictive values could not be estimated. Second, the PPVs obtained in
the present study apply only to patients using the study antidepres-
sant drugs who did not have preexisting liver disease or risk factors
for developing ALI. Third, PPVs are dependent on the ALI case defi-
nition used. In the present study, we used the definition created by
Aithal et al,19 but there are other case definitions that could be
used24,25 and PPVs could have been different with those other case
definition criteria. Finally, PPVs are dependent on ALI prevalence.
Therefore, the PPVs observed in our study might not apply directly
to patient populations with characteristics different from those
included in the present study or to studies using different case
definitions.5 | CONCLUSIONS
The PPVs obtained in this study apply to patients using antidepres-
sants without preexisting liver disease or risk factors for ALI. Future
studies evaluating ALI in these and similar data sources should priori-
tize use of hospital discharge and specific codes to maximize validity.
Moreover, case‐identifying algorithms should include hospital ICD
codes for unspecified jaundice. In studies including nonspecific codes
and outpatient cases, case validation is essential.
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